A primary care guide to the screening and pharmacologic management of chronic kidney disease in people living with type 2 diabetes

Sep 3, 2025Primary care diabetes

How Primary Care Can Screen and Treat Chronic Kidney Disease in People with Type 2 Diabetes

AI simplified

GLP-1 TherapiesGLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Primary care physicians recommend early and regular screening for chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D).

  • CKD screening should include estimated glomerular filtration rate and urinary albumin-to-creatinine ratio testing.
  • Annual review of CKD risk using a specific heatmap can help optimize treatment and slow CKD progression.
  • Lifestyle modifications are essential for reducing CKD risk in those with T2D.
  • A combination approach to medication is advised, including renin-angiotensin system inhibitors and sodium-glucose cotransporter 2 inhibitors, among others.

AI simplified

Full Text

Full text is available at the source.
View full text (XML) ↗View full text ↗

Related papers

Feb '25
Combined effects of finerenone and empagliflozin in people with chronic kidney disease and type 2 diabetes: baseline health features
top 10% journal
cited by 12 papers
randomized controlled trial
Sep '18
Insulin and blood sugar-lowering medicines for people with diabetes and long-term kidney disease
cited by 42 papers
systematic review
May '25
Glucagon-like peptide-1 drugs vs. sodium/glucose transporter inhibitors for reducing kidney failure and death in type 2 diabetes patients with kidney disease
top 5% journal
cited by 3 papers
comparative study
Feb '25
GLP-1 receptor drugs for people with diabetes and long-term kidney disease
cited by 10 papers
systematic review

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #28
Semaglutide linked to 74-fold higher risk of vision-threatening eye condition
1 week ago3 studies
issue #27
GLP-1 drugs linked to 18% lower risk of substance use disorders in 524,817 veterans
2 weeks ago7 studies
issue #26
86.5% of patients on semaglutide or tirzepatide lost at least 5% of body weight at 6 months in Medicaid study
3 weeks ago7 studies
issue #25
GLP-1 drugs linked to 20% lower dementia risk in diabetic kidney patients
4 weeks ago7 studies
issue #24
Tirzepatide beats semaglutide for weight loss by 6.1% in head-to-head comparison
5 weeks ago7 studies
issue #23
Bariatric Surgery vs. GLP-1s for cardiovascular risk
6 weeks ago7 studies
issue #22
GLP-1 drugs linked to better pregnancy rates in PCOS women and reduced cancer risk in diabetes patients
7 weeks ago7 studies
issue #21
GLP-1 drugs may fight addiction, and reduce alcohol consumption
8 weeks ago7 studies
issue #20
GLP-1 drugs show promise for kidney transplant patients and Alzheimer's, but may increase eye problems
9 weeks ago7 studies
issue #19
GLP-1 drugs cut heart attack risk by 22% vs competitors, but may increase vision loss risk
10 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief